RTI International announced a strategic equity investment in Navidence as the organizations expand efforts to standardize how diseases, treatments, and outcomes are defined in real-world evidence (RWE) research.
The partnership combines RTI’s scientific research and healthcare evidence expertise with Navidence’s AI-native data and medical informatics platform, according to the announcement published by RTI on May 5.
RTI said the collaboration will focus on improving consistency and reproducibility across clinical research and healthcare studies, where inconsistent operational definitions often create challenges in comparing datasets, validating findings, and generating regulatory-grade evidence.


